Biogen inks $1.15B HI-Bio buyout to expand in immunology

HI-Bio is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications.

Related Keywords

China ,Chris Viehbacher ,Priya Singhal ,Novartis ,Johnson ,Human Immunology Biosciences ,San Francisco Based ,Bay Area ,